Taylor & Francis Group
Browse
lbps_a_1695625_sm0482.pdf (151.24 kB)

Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials

Download (151.24 kB)
journal contribution
posted on 2019-12-10, 10:23 authored by Shogo Nomura, Tomohiro Shinozaki, Chikuma Hamada

In recent placebo-controlled randomized phase 3 oncology trials, evaluation of overall survival with frequent crossover is crucial for regulatory and pricing decisions. The problem is that an intention-to-treat based analysis causes a substantial loss of power to detect causal survival effect without crossover, and performance of existing methods is not satisfactory. In this article, our aims were to evaluate properties of the existing and a proposed Bayesian power prior method where data from an external trial is available. Simulation results suggested that proposed method was the most powerful under typical scenarios where patients with better prognosis are likely to crossover.

History

Usage metrics

    Journal of Biopharmaceutical Statistics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC